Samsung BioLogics lands multi-million dollar deal with Swiss-based pharmaceutical firm
- 4 years ago
삼성바이오, 스위스 제약사와 바이오의약품 생산 수주 계약
Samsung BioLogics says it has signed a statement of intent for biomedicine contract manufacturing with a Swiss-based pharmaceutical company.
The deal is worth over 36-million U.S. dollars.
Not much is known about it because of the confidentiality obligation in management,... but details like the other party or the term of a contract will be disclosed in 2024.
However, we do know that production will be done at Samsung BioLogics' third plant in Songdo, west of Seoul.
On top of that, the current figure is a fixed minimum and could rise to 400-million dollars if certain conditions are met in the future.
Samsung BioLogics says it has signed a statement of intent for biomedicine contract manufacturing with a Swiss-based pharmaceutical company.
The deal is worth over 36-million U.S. dollars.
Not much is known about it because of the confidentiality obligation in management,... but details like the other party or the term of a contract will be disclosed in 2024.
However, we do know that production will be done at Samsung BioLogics' third plant in Songdo, west of Seoul.
On top of that, the current figure is a fixed minimum and could rise to 400-million dollars if certain conditions are met in the future.